ReachRxResearch
Home
Research
Sign Up
A Two‐Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p‐Tau217 Gray Zone
Back to Research Hub
  1. Home
  2. Research Hub
  3. A Two‐Stage Plasma Biomarker Algorithm R…

A Two‐Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p‐Tau217 Gray Zone

Annals of Clinical and Translational Neurology·October 19Open Access
Clinical NeurologyPractice changingAlzheimer'S DiseaseMild Cognitive ImpairmentPreclinical Alzheimer'S DiseaseDiagnostic Accuracy Study With External ValidationAmyloid PETPlasma Biomarker AlgorithmOlder AdultLumipulse GAmyloid Beta 42/40 RatioFlorbetapirGlial Fibrillary Acidic ProteinPhosphorylated Tau 181Phosphorylated Tau 217

Summary

View source

What was studied

The GRAD (Gatekeeper-Reflex for Alzheimer's Disease) two-stage plasma algorithm was developed in 145 cognitively impaired ADNI participants and externally validated in 1,644 cognitively unimpaired A4/LEARN participants to reduce amyloid PET use by improving Aβ-positivity classification in the p-Tau217 'gray zone' (indeterminate probability 0.25–0.75), using additional plasma biomarkers (GFAP, Aβ42/40), APOE ε4 status, and age in Stage 2.

Key findings

In the external gray zone (n=630), Stage 2 improved AUC over p-Tau217 alone (0.793 vs. 0.719, p<0.001), raised correct classification without PET from 41.4% to 56.2%, and cut PET referral from 35.9% to 24.3%; overall, 90.7% of A4/LEARN participants were classified without PET, and modeled costs were 44–52% lower than p-Tau217 screening with PET for all gray-zone cases (~$863 vs. $1,639 per correct diagnosis).

Study limitations

Both cohorts are predominantly White (89–94%) and highly educated, limiting generalizability to diverse populations; the development gray zone is small (n=49) and the Stage 2 AUC gain was non-significant internally (p=0.54); calibration did not transfer to the external cohort (intercept shift +0.93), meaning predicted probabilities may require recalibration before clinical use; renal function and comorbid proteinopathies—known confounders of plasma biomarker levels—were not accounted for.

Clinical implications

For patients with indeterminate p-Tau217 results, a reflex multimarker panel (adding Aβ42/40 and APOE ε4 status) can reclassify over half without needing amyloid PET, potentially cutting imaging costs by 44–52%; however, GRAD requires prospective validation in diverse clinical populations and should currently be used as a triage and trial-enrichment aid rather than a replacement for confirmatory Aβ-PET.

Caveats

  • Aβ42/40 and GFAP were only available in roughly 56% of participants in both cohorts; missing values were median-imputed from training data, and the complete-panel sensitivity analysis showed a different Aβ prevalence profile (55.7% vs. 87.1%), so imputation effects cannot be fully ruled out
  • Cost savings are modeled hypothetically using 2024 U.S. Medicare rates and do not include geographic variation, clinician time, downstream treatment costs, or the economic consequences of misclassification including ARIA risk from false-positive DMT eligibility
  • The development cohort (n=145) is small and cognitively impaired (MCI/AD dementia), while the validation cohort (n=1,644) is cognitively unimpaired, making direct performance comparison across cohorts difficult and limiting applicability to populations bridging both groups

Related Questions

Explore related topics

How can plasma biomarker panels like p-Tau217, Aβ42/40, and APOE status reduce the need for amyloid PET in Alzheimer's diagnosis?What strategies are available to resolve the p-Tau217 gray zone in patients being evaluated for anti-amyloid therapy eligibility?What are the Alzheimer's Association guidelines for using blood-based biomarkers as triage tests in memory clinic settings?

Publication Details

Year
2026
Journal
Annals of Clinical and Translational Neurology
Sample Size
n=1,789
Source
View article
Keep scrolling
More content below.
Up Next